nirogacestat,lenalidomide,teclistamab,daratumumab,pomalidomide,bortezomib
takeda,springworks therapeutics,janssen,genmab,bms
['majestec2', 'lenalidomide', 'daratumumab', 'teclistamab', 'majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)']
#ash22 #majestec2 trial w/ fully immunotherapy-based triplet using teclistamab-daratumumab-lenalidomide showing impressive response rates (&gt;vgpr 90%) and no &gt;gr 3 crs/icans. higher response than tec single agent though with neutropenia. majestec7 in #ndmm would be pivotal. 
Hematology-Oncology fellow @MountSinaiNYC????????? 
Interests: #mmsm #lymsm #CART #cellulartherapy